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Abstract
Background: Autotaxin (ATX) is a secreted glycoprotein with the lysophospholipase D (lysoPLD) activity to convert
lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA), a bioactive lysophospholipid involved in diverse
biological actions. ATX is highly expressed in some cancer cells and contributes to their tumorigenesis, invasion,
and metastases, while in other cancer cells ATX is silenced or expressed at low level. The mechanism of ATX
expression regulation in cancer cells remains largely unknown.
Results: In the present study, we demonstrated that trichostatin A (TSA), a well-known HDAC inhibitor (HDACi),
significantly induced ATX expression in SW480 and several other cancer cells with low or undetectable
endogenous ATX expression. ATX induction could be observed when HDAC3 and HDAC7 were down-regulated by
their siRNAs. It was found that HDAC7 expression levels were low in the cancer cells with high endogenous ATX
expression. Exogenous over-expression of HDAC7 inhibited ATX expression in these cells in a HDAC3-dependent
manner. These data indicate that HDAC3 and HDAC7 collaboratively suppress ATX expression in cancer cells, and
suggest that TSA induce ATX expression by inhibiting HDAC3 and HDAC7. The biological significance of this
regulation mechanism was revealed by demonstrating that TSA-induced ATX protected cancer cells against TSA-
induced apoptosis by producing LPA through its lysoPLD activity, which could be reversed by BrP-LPA and S32826,
the inhibitors of the ATX-LPA axis.
Conclusions: We have demonstrated that ATX expression is repressed by HDAC3 and HDAC7 in cancer cells.
During TSA treatment, ATX is induced due to the HDAC3 and HDAC7 inhibition and functionally antagonizes the
TSA-induced apoptosis. These results reveal an internal HDACi-resistant mechanism in cancer cells, and suggest
that the inhibition of ATX-LPA axis would be helpful to improve the efficacy of HDACi-based therapeutics against
cancer.
Introduction
Autotaxin (ATX), also known as nucleotide pyropho-
sphatase/phosphodiesterase 2 (NPP2), is an exo-enzyme
originally identified as a tumor cell autocrine motility
factor [1]. Different from NPP1 and NPP3, ATX is
synthesized as a pre-pro-enzyme, and the removal of the
propeptide by furin-like proteases is required for its full
activation [2]. ATX is present in most biological fluids,
including cerebro-spinal fluid, plasma, peritoneal fluid,
urine, and synovial fluid [3], with the lysophospholipase
D (lysoPLD) activity converting lysophosphatidylcholine
( L P C )i n t ol y s o p h o s p h a t i d i ca c i d( L P A )[ 4 ] .I th a sb e e n
reported that ATX is rapidly cleansed from the circula-
tion by liver sinusoidal endothelial cells (LSECs) [5].
ATX deficiency in mouse leads to embryonic lethality,
indicating that ATX is required for normal develop-
ment. Compared with the wild-type mice, ATX hetero-
zygous mice develop normally, but have half plasma
LPA levels [6,7]. Therefore, ATX is regarded as a major
enzyme to produce LPA in the blood and potentially
other biological fluids. Many, if not all, biological func-
tions of ATX appear to be mediated by LPA signaling.
LPA acts on specific G protein-coupled receptors to
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any medium, provided the original work is properly cited.regulate a wide range of cellular activities, ranging from
cell proliferation, differentiation, migration, to anti-
apoptosis [8]. To date, at least six LPA receptors have
been identified and additional unidentified LPA recep-
tors may still exist [9]. The best-known LPA receptors
are LPA1,L P A 2,a n dL P A 3, which are members of the
endothelial differentiation gene (EDG) family [9]. The
broad range of LPA cellular functions is accomplished
by the different LPA receptors differentially coupled to
distinct G proteins (Gq, Gi and G12/13) and their
down-stream signaling molecules, including phospholi-
pase C, PI3K, Ras-MAPK, Rac, and Rho [10].
ATX plays roles in the immune [11] and the nervous
systems [12], as well as in angiogenesis [13,14]. In addi-
tion, the significant functions of the ATX-LPA axis have
been demonstrated in several cancer types. Autotaxin
(ATX), which was initially isolated as a prometastatic
enzyme from the conditional medium of human mela-
noma cells [1], is over-expressed in several human can-
cers and contributes to their progression, such as non-
small cell lung cancer, breast cancer, renal cell cancer,
prostate cancer, hepatocellular carcinoma, thyroid can-
cer and neuroblastoma [15]. Ectopic expression of ATX
in ras-transformed NIH3T3 cells stimulates their tumor-
igenesis and metastatic potential [16]. ATX largely
accounts for the motility of MDA-MB-435 cells [17],
and the expression of ATX and lysophosphatidic acid
receptors increases mammary tumorigenesis [18]. ATX-
LPA axis also facilitates cancer cells survival under drug
treatment. It has been reported that ATX protects
MDA-MB-435 cells against taxol-induced apoptosis and
delays apoptosis induced by carboplatin in OVCAR-3
ovarian cancer cells through LPA generation [19,20].
Therefore, ATX is regarded as an attractive target of
cancer therapy [21].
ATX expression is inducible by VEGF, EGF, bFGF and
BMP-2, but inhibited by TGF-b and several cytokines,
including IL-1, IL-4 and IFN-g [15]. We have recently
reported that ATX expression is regulated by TNF-a in
human hepatocellular carcinoma [22]. However, most of
these regulations are cell type- and/or context-specific.
The endogenous ATX expression is high in some cancer
cells, but low or undetectable in other cancer cell types
[23]. Hence, the mechanisms by which endogenous
ATX expression is regulated in cancer cells remain to
be further explored.
Histone deacetylases (HDACs) comprise of a family of
18 genes, which are grouped into classes I-IV based on
their homology to their respective yeast orthologues [24].
In addition to histone proteins, HDACs have many non-
histone protein substrates which play roles in gene
expression regulation [25]. HDACs are involved in var-
ious cellular processes, such as DNA replication, cell
cycle progression, gene silencing, cell differentiation and
tumorigenesis [26]. HDAC inhibitors (HDACis) consti-
tute a new group of epigenetic agents that has gained
much attention in cancer drug development in recent
years. HDACis exhibit their anticancer activities by indu-
cing cell cycle arrest, cell differentiation, and apoptosis
[27]. HDACi treatment increases protein acetylation
leading to transcriptional activation of genes involved in
cell apoptosis. These inhibitors can up-regulate the
expression of both death receptors and their ligands in
vitro and in vivo in transformed cells, but not in normal
cells [28]. More than 10 structurally different HDACis
are currently (or have been tested) in anti-cancer clinical
trials, such as suberoylanilide hydroxamic acid (SAHA),
valproic acid (VPA), and PXD-101 [25]. However, resis-
tant to the HDACi treatment has been reported in cer-
tain cancer cells in pre-clinical experiments and patients
in clinical trials. It is necessary and important to under-
stand the mechanisms of HDACi resistance and develop
methods to overcome the resistance [29].
In this study, we demonstrated that TSA, a well-
known HDACi, induced ATX expression in various can-
cer cell lines. HDAC3 and HADC7, as the targets of
TSA, were involved in ATX expression regulation in
cancer cells. The TSA-induced ATX protected cancer
cells from TSA-induced apoptosis by producing LPA
through its lysoPLD activity, while BrP-LPA and
S32826, the inhibitors of ATX-LPA axis, promoted the
TSA-induced apoptosis. These results suggest that inhi-
bition of ATX-LPA axis would potentially improve the
efficacy of HDAC inhibitors in cancer treatment.
Results
HDAC inhibitors induce ATX expression in cancer cells
To investigate whether ATX expression is epigenetically
regulated in cancer cells, we tested the roles of DNA
methylation and protein acetylation in ATX expression
in a colon cancer cell line SW480, where endogenous
ATX expression was not detectable. HDAC inhibitor tri-
chostatin A (TSA), but not 5-aza-2’-deoxycytidine, an
inhibitor of DNA methylation, induced ATX expression
in SW480 cells (Figure 1A). This induction was dose-
and time-dependent at both RNA and protein levels
(Figure 1B and Figure 1C). Moreover, TSA induced a
time-dependent increase of lysoPLD activity in cell cul-
ture medium (Figure 1D), which was correlated well
with the increase of secreted ATX protein (Figure 1C).
To determine whether the ATX induction ability is lim-
ited to TSA, other HDAC inhibitors were used to treat
SW480 cells. Similar to TSA, sodium butyrate (NaB)
and valproic acid (VPA) also induced ATX expression
in SW480 cells (Figure 1E), suggesting that HDAC(s) is
involved in ATX expression regulation.
A panel of different cancer cell lines was used to test
whether ATX induction by TSA is limited to SW480
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cell types, including breast, cervical, lung, ovarian, and
prostate cancer cells (Figure 1F). Furthermore, NaB and
VPA also could induce ATX expression in various can-
cer cells other than SW480 (additional file 1). The
broad range of ATX induction by HDACi in cancer
cells indicates the generality and importance of ATX
expression regulation by protein acetylation. However,
this effect was not universal, since TSA failed to induce
ATX expression in a few cell lines tested, including HT-
29, LNcap and Jurkat cells (data not shown).
Down-regulation of HDAC3 and HDAC7 induces ATX
expression in cancer cells
TSA inhibits the Class I and II, but not Class III
HDACs. More specifically, TSA strongly inhibits
HDAC1, HDAC2, HDAC3, HDAC4, HDAC6 and
HDAC7 [24]. To identify the TSA target(s) involved in
A T Xi n d u c t i o n ,H D A C 1 ,H D A C 2 ,H D A C 3 ,H D A C 4 ,
HDAC6, and HDAC7 were individually down-regulated
with their specific siRNAs. At least 50% down-regulation
was achieved for each of these HDACs. However, none
of the respective HDAC knockdown led to a significant
Figure 1 TSA induces ATX expression in various cancer cell types. A, SW480 cells were treated with Aza (5 μM) for 48 hrs or TSA (100 nM)
for 24 hrs, followed by ATX mRNA detection by RT-PCR. B, SW480 cells were treated with the indicated concentrations of TSA for 24 hrs. The
ATX mRNA expression in cells and ATX protein in the conditional medium were detected by RT-PCR and Western blotting analyses, respectively.
C, SW480 cells were treated with TSA (100 nM) for 0, 6, 12, or 24 hrs. After TSA treatment, the ATX mRNA expression in cells and secreted ATX
protein in the conditional medium were examined by real-time RT-PCR and Western blotting analyses, respectively. D, LysoPLD activity in the
conditional medium was determined with FS-3 as substrate after TSA treatment for indicated times. E, SW480 cells were treated with VPA (1
mM), NaB (1 mM), or TSA (100 nM) for 24 hrs. The ATX mRNA expression was evaluated by real-time RT-PCR. F. The indicated breast, cervical,
lung, ovarian, and prostate cancer cell lines were treated with or without TSA (100 nM for 24 hrs), and then ATX mRNA expression levels were
detected by RT-PCR. The p values derived from Student’s t test are (*) p < 0.005, (**) p < 0.001.
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file 2). These data suggest that either these HDACs are
not functionally involved in ATX expression regulation
or a combination of more than one HDAC is involved.
We tested different combinations of siRNAs against
HDACs, and found that only the combination of siRNAs
against HDAC3 and HDAC7 induced ATX expression
in SW480 cells (Figure 2A). Other Class I and II HDAC
siRNA combinations including the siRNAs against
H A D C s1a n d4 ,1a n d7 ,o r3a n d4w e r ei n e f f e c t i v e
(Figure 2A). The down-regulation of HDAC3 and
H D A C 7b yc o - t r a n s f e c t i o no ft h e i rs i R N A sw a sc o n -
firmed by Western blot analyses, and ATX expression
was tested at the protein level in the conditional med-
ium and the RNA level in SW480 cells (Figure 2B). To
verify the effect of HDAC3/HDAC7 on ATX expression
further, siRNAs against these two HDACs were co-
transfected into several additional cell lines, including
Hela, MDA-MB-231, A2780, and Du145 cells. Up-regu-
lation of ATX expression was observed in all of these
cell lines when HDAC3 and HDAC7 were down-regu-
lated together (Figure 2C). Collectively, our data indicate
that HDAC3 and HDAC7 play a critical negative
regulatory role of in ATX expression, and serve as TSA
targets in the ATX induction in cancer cells.
Exogenous over-expression of HDAC7 inhibits ATX
expression in cancer cells in a HDAC3-dependent manner
To expand our studies on the role of HDACs in ATX
expression, we examined expression levels of HDAC3,
HDAC7 and ATX in 13 cancer cell lines. The levels of
HDAC3 expression were almost similar in all of cell
lines tested, while the levels of HDAC7 expression had
an inverse correlation with those of ATX expression. In
particular, in 10 cancer cells with relatively high
HDAC7 expression, the endogenous ATX expression is
low or undetectable (Figure 3A, lines 1-9 and line 13).
The functional effects of HDAC7 and HDAC3 on ATX
expression were examined further using a gain-of-function
approach in Du145, colo320, and MDA-MB-435 cells,
where low levels of endogenous HDAC7, but high levels
of endogenous ATX, were expressed (Figure 3A, lines 10
to 12). Exogenous over-expression of HDAC7 significantly
inhibited ATX expression in these cancer cells (Figure
3B), suggesting that HDAC7 is an important negative reg-
ulator of ATX expression. On the other hand, exogenous
Figure 2 Knockdown of HDAC3 and HDAC7 up-regulates ATX expression in cancer cells.A ,S W 4 8 0c e l l sw e r ec o - t r a n s f e c t e dw i t ht h e
indicated Class I and Class II HDAC siRNAs. ATX mRNA expression was detected by RT-PCR 48 hrs post transfection. B, SW480 cells were co-
transfected with HDAC3 and HDAC7 siRNAs. ATX expression at the RNA (in cells) and protein levels (in culture medium) were detected 48 hrs
post transfection by real-time RT-PCR and Western blotting, respectively. C, HDAC3 and HDAC7 siRNAs were co-transfected into Hela, MDA-MB-
231, A2780, and Du145 cells, respectively, with non-specific siRNA (siNC) as a control. Real-time RT-PCR was used for detecting ATX mRNA
expression. The p value derived from Student’s t test is (**) p < 0.001.
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(Figure 3C), but the functional involvement of HDAC3 in
ATX regulation was confirmedb yi t sd o w n - r e g u l a t i o n .
When the Du145, colo320 or MDA-MB-435 cells were
pre-transfected with HDAC3 siRNA, the ATX expression
inhibited by HADC7 over-expression was significantly
restored (Figure 3D). These data indicate that the exogen-
ous over-expression of HDAC7 inhibits ATX expression
in a HDAC3-dependent manner, and suggest that HDAC7
and HDAC3 collaboratively suppress ATX expression in
cancer cells.
TSA-induced ATX protects cancer cells against TSA-
induced apoptosis through its lysoPLD activity
SW480 cells are HDACi sensitive [30] with ~30% cells
undergoing apoptosis after TSA (250 nM) treatment for
24 hrs in the serum-free conditional medium. Since the
ATX-LPA axis has been shown to be involved in cell sur-
vival and/or proliferation in many cancer cell types [3], we
tested whether LPC (the substrate of ATX) or LPA (the
product of ATX) had effects on TSA-induced cell apopto-
sis. In the presence of LPC (100 μM) or LPA (5 μM),
SW480 cells were protected against the TSA-induced
apoptosis (Figure 4A). As described above, the secreted
ATX protein and the lysoPLD activity in culture medium
were increased upon TSA treatment (Figure 1C and Figure
1D). We checked the LPA production by liquid chromato-
graphy/Mass spectrometry (LC-MS) analysis after incubat-
ing the conditional culture medium with ATX substrate
LPC (100 μM, 18:1-LPC). In the presence of LPC, the
medium of SW480 cells without TSA treatment contained
low levels of LPA (0.13 ± 0.01 μM, 18:1-LPA), while the
Figure 3 Exogenous over-expression of HDAC7 inhibits ATX expression in cancer cells in a HDAC3-dependent manner. A, HDAC3 and
HDAC7 protein levels, as well as ATX mRNA levels, were detected by Western blot and RT-PCR analyses, respectively, in 13 cancer cell lines (1,
MDA-MB-231; 2, MCF-7; 3, MDA-MB-468; 4, Hela; 5, A549; 6, A2780; 7, HEY; 8, OCC1; 9, PC3; 10, Du145; 11, MDA-MB-435; 12, colo320; 13, HT-29). B
and C, HDAC7 (B) or HDAC3 (C) over-expression plasmid was transfected into indicated cancer cells with empty vector as the control. ATX
mRNA expression was detected by real-time RT-PCR 48 hrs post transfection. D, The indicated cancer cells were first transfected with non-
specific siRNA (siNC) or HDAC3 siRNA for 24 hrs, followed by transfection of the HDAC7 over-expression plasmid. ATX mRNA expression levels
were detected by real-time RT-PCR 48 hrs post the second transfection. The p values derived from Student’s t test are (*) p < 0.005, (**) p <
0.001.
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levels by about 12.0-fold (1.56 ± 0.40 μM 18:1-LPA, P <
0.001) (Figure 4B). These data suggest that LPC is con-
verted to LPA by TSA-induced ATX to protect cells from
apoptosis. Indeed, when ATX was down-regulated by
siRNA in SW480 cells to block the TSA-induced ATX
expression, the protective effect of LPC, but not that of
LPA, against TSA-induced cell apoptosis was significantly
reduced (Figure 4C). Therefore, HDACis, including TSA,
have dual effects to induce cell apoptosis and ATX expres-
sion at the same time, and ATX can antagonize the
HDACi-induced apoptosis by producing LPA through its
lysoPLD activity.
ATX-LPA axis protects cells from TSA-induced apoptosis
via cell-specific LPA receptors
The biological function of ATX is to convert LPC into
LPA, a bioactive lysophospholipid that acts on specific
G protein-coupled receptors (GPCRs) to perform var-
ious biological activities, including the anti-apoptosis
activity. Quantitative PCR analyses showed that LPA2
was the dominant LPA receptor expressed in SW480
cells (Figure 5A). Down-regulation of LPA2 by siRNA
enhanced TSA-induced cell apoptosis in the presence of
LPC or LPA (Figure 5A), while down-regulation of
either LPA1 or LPA3 did not have such an effect (data
not shown), indicating that LPA2 is involved in the pro-
tective effect of ATX-LPA signaling.
Similar to SW480 cells, MDA-MB-231 cells were sen-
sitive to TSA and were protected by LPA and LPC from
the TSA-induced apoptosis (data not shown). In MDA-
MB-231 cells, LPA1 was the dominant LPA receptor
expressed (Figure 5B). The protective effect of LPC
against TSA-induced MDA-MB-231 cell apoptosis was
significantly inhibited by the down-regulation of ATX or
LPA1 (Figure 5B), but not by that of LPA2 or LPA3
Figure 4 The TSA-induced ATX protects cancer cells from TSA-induced apoptosis through its lysoPLD activity. A, SW480 cells were
treated with or without TSA (250 nM) for 24 hrs in the presence of LPC (100 μM) or LPA (5 μM) in the serum-free conditional medium
containing 250 μg/ml fatty-acid free BSA, and then the apoptosis of SW480 cells were measured. B, SW480 cells were treated with or without
TSA (250 nM) for 24 hrs, and then the concentrated conditional media (30-fold) were incubated with 100 μM LPC (18:1) for 6 hrs at 37°C. Lipids
were extracted and analyzed by liquid chromatography-mass spectrometry (LC-MS). The levels of LPA (18:1) were obtained from three
experiments. C, ATX siRNA was transfected into SW480 cells to block the ATX induction by TSA with non-specific siRNA (siNC) as the control.
After siRNA transfection for 48 hrs, SW480 cells were treated with or without TSA (250 nM) in the presence of LPC (100 μM) or LPA (5 μM). The
apoptosis of SW480 cells was measured after TSA treatment for 24 hrs. The p value derived from Student’s t test is (**) p < 0.001.
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MDA-MB-231 cell from the TSA-induced apoptosis
through the LPA1-mediated signaling. Collectively, our
data suggest that the cell-specific LPA receptor(s) is
involved in the LPC-ATX-LPA signaling axis, which
plays a role in reducing the efficacy of apoptosis induc-
tion by TSA and potentially other HDACi.
Inhibitor of the ATX-LPA axis enhances the TSA-induced
cell apoptosis
HDACis have been rapidly moved from the laboratory
bench to clinical trials as novel anticancer agents [27].
As described above, the TSA-induced ATX could con-
vert LPC to LPA through its lysoPLD activity and pro-
tect the cancer cells from TSA-induced apoptosis via
LPA receptor-mediated signaling. Furthermore, we test
whether ATX-LPA axis inhibition would increase the
efficacy of apoptosis induction by TSA. BrP-LPA is a
potent ATX inhibitor and a pan LPA receptor antago-
nist, which not only inhibits the ATX lysoPLD activity
but also blocks LPA receptor-mediated signaling
[31-33]. As predicted, the lysoPLD activity in the condi-
tional culture medium of TSA-treated SW480 cells was
significantly inhibited by BrP-LPA (additional file 3A).
In the presence of either LPC or LPA, combination of
TSA and BrP-LPA induced higher percentage of apopto-
tic death in SW480 cells, compared with treatment with
TSA alone (Figure 6A). In the presence of either LPC or
LPA, MDA-MB-435 and colo320 cells, which express
high endogenous levels of ATX, were relatively resistant
to TSA treatment, while addition of BrP-LPA significantly
enhanced the TSA-induced apoptosis in MDA-MB-435
Figure 5 The TSA-induced ATX protects cancer cells from TSA-induced apoptosis through cell specific LPA receptor-mediated
signaling. A, The mRNA expression levels of LPA1, LPA2 and LPA3 in SW480 cells were examined by real-time RT-PCR. SW480 cells were
transfected by LPA2 siRNA with non-specific siRNA (siNC) as control. After siRNA transfection for 48 hrs, SW480 cells were treated with or without
TSA (250 nM) in the presence of LPC (100 μM) or LPA (5 μM). The apoptosis of SW480 cells were measured after TSA treatment for 24 hrs. B, The
mRNA expression levels of LPA1, LPA2 and LPA3 in MDA-MB-231 cells were examined by real-time RT-PCR. MDA-MB-231 cells were transfected by
ATX or LPA1 siRNA with non-specific siRNA (siNC) as control. After siRNA transfection for 48 hrs, MDA-MB-231 cells were treated with or without
TSA (250 nM) in the presence of LPC (100 μM). The apoptosis of MDA-MB-231 cells was measured after TSA treatment for 24 hrs. The p value
derived from Student’s t test is (**) p < 0.001.
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another ATX inhibitor with the IC50 in nanomolar
range (additional file 3B) [34], was used to testify the
effects of combinational treatment with ATX inhibitor
and TSA. In the presence of LPC, S32826 obviously
enhanced the TSA-induced apoptosis in SW480,
colo320, MDA-MB-231 and MDA-MB-435 cells (addi-
tional file 4). However, compared with BrP-LPA,
S32826 could not promote cell apoptosis in the pre-
sence of LPA because S32826 is not a LPA receptor
antagonist (additional file 4A). These data suggest that
the ATX-LPA axis inhibition is able to improve the effi-
cacy of cancer treatment with HDACi.
Discussion
ATX is the primary enzyme to produce LPA, a bioactive
phospholipid inducing cell proliferation, survival and
migration. ATX-LPA signaling axis is critically involved
in the development and progression of several cancers.
It is found that ATX is highly expressed in some cancer
cells and contributes to their tumorigenesis, invasion,
and metastases, while in other cancer cells ATX is
silenced or expressed at low level [23]. In the present
paper, we have demonstrated that HDAC3 and HDAC7
are involved in the endogenous ATX expression regula-
tion, which is supported by the loss- and gain-of-func-
tion studies in multiple cancer cell lines. Down-
regulation of both HDAC3 and HDAC7 up-regulated
ATX expression in the cancer cells with low ATX
expression, while over-expression of HDAC7 inhibited
ATX expression in a HDAC3-dependent manner in the
cancer cells with high endogenous ATX expression,
indicating that HDAC3 and HDAC7 collaboratively sup-
press ATX expression in cancer cells. There is evidence
that the HDAC activity of HDAC7 is dependent on the
interaction with HDAC3, which is mediated by the
Figure 6 Inhibitor of ATX-LPA signaling enhances the TSA-induced cell apoptosis. A, The SW480 cells were pretreated with BrP-LPA (10
μM) for 1 hr, and then treated with TSA (250 nM) in the presence of LPC (100 μM) or LPA (5 μM). The apoptosis of SW480 cells were measured
after TSA treatment for 24 hrs. B and C, MDA-MB-435 (B) and colo320 cells (C) were treated with TSA (250 nM) with or without the pre-
treatment of BrP-LPA (10 μM) in the presence of indicated lipids in serum-free conditional medium. The cell apoptosis was measured after TSA
treatment for 24 hrs. The p value derived from Student’s t test is (**) p < 0.001.
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fore, it is possible that the HDAC3/HDAC7 complex is
involved in ATX expression regulation.
In the 13 tested cancer cell lines, HDAC3 was almost
constitutively expressed, but the expression levels of
HDAC7 were inversely correlated to those of ATX, sug-
gesting that expression regulation of HDAC7 may play
an important role in the differential expression of ATX
observed in different cancer cell lines. It has been
reported that ATX expression is inducible by several
growth factors, such as VEGF [13,36] and BMP-2 [37].
Both VEGF and BMP-2 can enhance the phosphoryla-
tion of HDAC7 via protein kinase D, which promotes
nuclear export of HDAC7 [38,39]. Thus, it will be inter-
esting to test whether HDAC7 plays a role in the ATX
expression regulation by VEGF and BMP-2.
Acetylated histones are the major targets of HDACs,
and HDACi treatment leads to increased histone acety-
lation. Inhibiting HDACs by TSA leads to increased his-
tone acetylation, and histone H3 lysine 9 acetylation is a
hallmark of the TSA-induced histone acetylation [40].
We tested whether increased histone acetylation was
sufficient to induce ATX expression. In HT-29 cells,
TSA induced histone H3 acetylation, but not ATX
expression (additional file 5A). In SW480 cells, down-
regulation of HDAC3 alone, but not HDAC7, led to his-
tone H3 acetylation in the ATX promoter, while down-
regulation of both of these two HDACs was necessary
to induce ATX expression (additional file 5B). These
data suggest that histone acetylation in the ATX promo-
ter is insufficient to up-regulate ATX expression. A
number of non-histone proteins have been identified as
substrates of HDACs, among which there are transcrip-
tion factors and/or transcription regulators involved in
gene expression regulation [25]. The target protein(s) of
HDAC3/HDAC7 involved in ATX expression regulation
remains to be identified, which will be helpful to explain
why TSA cannot induce ATX expression in a few can-
cer cell lines including HT-29, LNcap and Jurkat cells.
HDACs play an important role in the cancer patho-
genesis, and HDAC-dependent aberrant transcriptional
repression is implicated as one of the main oncogenic
mechanisms. As a result, HDAC inhibitors have been
evaluated in clinical trials for solid tumors and hemato-
logical malignancies [41]. However, resistant to the
HDACi becomes a major obstacle of these reagents. The
proposed mechanisms of HDACi resistance include up-
regulation of cellular antioxidant pathways, increased
expression of the anti-apoptotic protein Bcl-2 and the
stress-responsive transcription factor NF-B, and the
alternative gene silencing pathways such as DNA methy-
lation [42]. The current study illustrates that ATX
induction by HDACi is a novel mechanism with a
strong internal antagonism against the apoptotic effects
of HDACi on cancer cells. As a potential HDACi, TSA
leads to apoptotic cell death by inhibiting HDACs, but
releases the repression of ATX expression at the same
time by targeting HDAC3 and HDAC7. The induced
ATX produces LPA from LPC through its lysoPLD
activity and antagonizes the TSA-induced cell apoptosis
through the signaling pathway mediated by particular
cell-specific LPA receptor. As a rich source of both LPC
(the substrate of ATX) and LPA (the product of ATX),
serum protected MDA-MB-231 cells from TSA-induced
apoptosis significantly. In the serum-containing medium,
both ATX inhibitor S32826 and LPA1/3 inhibitor
Ki16425 could enhance the TSA-induced apoptosis of
MDA-MB-231 cells, in which LPA1 is involved in the
protective effect of ATX-LPA signaling (additional file
6). These data implicate that, besides the anti-apoptotic
cytokines and growth factors in serum, the LPC-ATX-
LPA axis plays a role to protect cancer cells from TSA-
induced apoptosis.
ATX is secreted through the classical secretory path-
w a y[ 2 ] ,a n di sr a p i d l yt a k e nu pf r o mc i r c u l a t i o na n d
degraded by a general mechanism of the liver LSEC sca-
venger system [5], which leaves little space for specific
interference with its secretion or promotion of its clear-
ance. Therefore, the exploring of ATX inhibitors is
highly focused in cancer therapy, and several ATX spe-
cific inhibitors have been developed in recent years
[43-45]. In the present paper, we have demonstrated
that inhibition of ATX lysoPLD activity with ATX inhi-
bitor (such as BrP-LPA and S32826) could enhance the
TSA-induced apoptosis in cancer cells. The combina-
tional treatment with ATX inhibitor and HDACi would
be helpful to improve the efficacy of HDACi-based ther-
apeutics against cancer.
Conclusions
In the present paper, we demonstrated a novel ATX
expression regulation mechanism in cancer cells, in
which HDAC3 and HDAC7 were involved as negative
regulators. During TSA treatment, ATX was induced
due to the HDAC3 and HDAC7 inhibition and func-
tionally antagonized the TSA-induced apoptosis. The
use of TSA combining with an ATX-LPA axis inhibitor
resulted in the increased apoptotic response in cancer
cells. These findings are significant to reveal an internal
HDACi-resistant mechanism generally existing in cancer
cells, and helpful to develop new combinational
approach to improve the efficacy of HDACi as che-
motherapeutic agent in cancer treatment.
Methods
Materials and reagents
5-AZA-2’-deoxycytidine, trichostatin A (TSA), sodium
butyrate (NaB), and Valproic acid (VPA) were purchased
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(lysoPLD/Autotaxin substrate), 1-Bromo-3(S)-hydroxy-
4-(palmitoyloxy) butylphosphonate (BrP-LPA) and 4-
(Tetradecanoylamino) benzyl phosphonic acid disodium
salt (S32826, ATX inhibitor) were obtained from Eche-
lon Biosciences (Salt Lake City, Utah). LPA1/3 inhibitor
Ki16425 was obtained from Cayman Chemical (Ann
Arbor, MI, USA). 18:1 lysophosphatidylcholine (LPC)
and 18:1 lysophosphatidic acid (LPA) were from Avanti
Polar Lipid Inc. (Alabaster, AL). The HDAC7 expression
plasmid was a kind gift from Dr. Hung-Ying Kao [46],
and the HDAC3 expression plasmid was from Dr.
Edward Seto’s lab [47].
Antibodies
The ATX primary antibody was generated as described
previously [48]. The primary antibodies against
HDAC7 and b-actin were purchased from Cell Signal-
ing Technology (Beverly, MA). The primary antibodies
against HDAC3 and HRP conjugated secondary anti-
body were from Santa Cruz Biotechnology (Santa
Cruz, CA). The antibodies against total histone H3 and
histone H3 Lys9 acetylation were obtained from Milli-
pore (Billerica, MA).
Cell Cultures, siRNA and transfections
The SW480, MDA-MB-231, MCF-7, MDA-MB-468,
Hela, A549, MDA-MB-435 and HT-29 cells were cul-
tured in Dulbecco’s modified Eagle’s medium (Hyclone).
A2780, HEY, OCC1, PC-3, Du145, and colo320 cells
were maintained in RPMI-1640 medium (Hyclone).
Mediums were supplemented with 10% fetal bovine
serum (Hyclone), 2 mM L-glutamine (Gibco), 100 μg/ml
streptomycin (Gibco) and 100 U/ml penicillin (Gibco).
All cells were cultured at 37°C in a humidified atmo-
sphere containing 5% CO2. For experiments to detect
the effects of LPA and LPC on cell apoptosis, the cancer
cells were cultured in a conditional serum-free medium
with 250 μg/ml fatty-acid free BSA as described pre-
viously [48]. All siRNAs were synthesized in Gene-
Pharma (Shanghai, China), and the target sequences
were: ATX-GUGGACCAAUCUUCGACUA; LPA1-
GAAAUGAGCGCCACCUUUA; LPA2-GGUCAAUG-
CUGCUGUGUAC; LPA3-CAGCAGGAGUUACCUU-
GUU; HDAC1-GCUUCAAUCUAACUAUCAA; HDAC2-
CAGUGAUGAGUAUAUCAAA; HDAC3-GCCGGUUA
UCAACCAGGUA; HDAC4-CGUCAACAUGGCUUU-
CACC; HDAC6-GCUCGGCCAAGCAAUGGAA; HDAC7-
UCACUGACCUCGCCUUCAA; non-specific-UUCUCC-
GAACGUGUCACGU. The siRNAs were transfected
into cells with lipofectamine 2000 (Invitrogen), accord-
ing to the protocol supplied by manufacturer. In each
siRNA transfection experiment, the non-specific siRNA
was used as control.
RNA Extraction, RT-PCR and Real-time RT-PCR
Total RNA was extracted from cancer cells with Trizol
(Invitrogen), and then digested with DNase I (Ambion) for
15 min at 37°C in order to remove DNA contamination.
RNA (2 μg) from cancer cells were reverse-transcribed
using anchored oligo dT (15) primers and the Reverse
Transcription System (Promega). The cDNAs encoding
indicated genes were amplified with specific primers. ATX
primers: 5’-TATGCTTCGGAAAGAAATGGAG-3’ and
5’-ATGTTCAATGTCACGCACCCT-3’; GAPDH primers:
5’-TTAGC ACCCCTGTCCAAGG-3’ and 5’-CCTACTCC
TTGGAGGCCATG-3’;H D A C 1p r i m e r s :5 ’-GAACTGG
GGACCTACGGG-3’ and 5’-GCTCTTGACAAATTCCA-
CACAC-3’;H D A C 2p r i m e r s : 5 ’-AGTTGCCCTTGATT
GTGAGA-3’ and 5’-CCACTGTTGTCCTTGGATTTAT-
3’;H D A C 3p r i m e r s : 5 ’-TGATGACCAGAGTTACAAG-
CAC-3’ and 5’-GGGCAACATTTC GGACAG-3’;H D A C 4
primers:5’-GTGCTGGTGTCATCAGGCTT-3’ and 5’-
AAATGGCG GTCAGGTCGT-3’;H D A C 6p r i m e r s : 5 ’-
TGCTGTGACACCACTGCCC-3’ and 5’-TTCT GGTGG
GCGATGTTCTT-3’;H D A C 7p r i m e r s5 ’-GGATTT-
GATGCTGCTGAGGG-3’ and 5’-CCACAGAGAGG-
GACGCCAG-3’; LPA1 primers:5’-CGGCGGGTAGTG
GTGGTC-3’ and 5’-GTCGCGGTAGGAGTAAATG
ATG-3’;L P A 2 primers: 5’-GTCGAGCCTGCTTG
TCTTCC-3’ and 5’-CCAGGAGCAGTACCACCTG-3’;
LPA3 primers: 5’-GACGGTGA TGACTGTCTTAGGGG-
3’ and 5’-GAGGACTGTGGAGGGGATGC-3’.T h eP C R
conditions were: 20 s at 95°C, 20 s for annealing, 25 s at
72°C for reasonable cycles, with a final extension for 5 min
at 72°C. Each RT-PCR experiment was repeated at least
three times with 3 parallel samples. The real-time RT-PCR
was performed using the iQ SYBR Green Supermix (Bio-
Rad) with the iCycler iQ real-time RT-PCR detection sys-
tem (Bio-Rad). Relative expression of each target gene was
estimated by normalization with the expression of
GAPDH.
ATX lysoPLD activity analyses
The conditional serum-free medium from cancer cells
with or without exposure to TSA was concentrated (30-
fold) using Amicon Ultra 30,000 (Millipore). The
lysoPLD activity in the concentrated conditional med-
ium was analyzed using fluorogenic substrate FS-3 as
described previously [48]. Briefly, the assays were per-
formed by mixing 50 μlc o n c e n t r a t e dm e d i u mw i t h1 0
μM FS-3 at 37°C for 4 hrs. LysoPLD activity was mea-
sured by detecting the fluorescence increase with 494
and 520 nm as the excitation and emission wavelengths,
respectively.
Lipid extraction and analyses
Lipids were extracted from concentrated (30-fold) con-
ditional medium of SW480 cells with or without TSA
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tandem mass spectrometry (LC-MS/MS) as described
previously [22].
Western blotting
Cells were lysed in RIPA buffer for 30 min. After cen-
trifugation, the supernatants were quantified by
bicinchoninic acid assay (Micro BCA; Pierce Biotech-
nology, Rockford, IL). For experiments detecting the
secreted ATX protein, the culture medium was con-
centrated (by approximately 30-fold) using Amicon
Ultra 30,000 (Millipore). Protein quantification was
conducted and equal amount protein was loaded for
each sample. Protein samples were subjected to SDS-
PAGE and analyzed as described previously [48]. Each
Western blot analysis was repeated at least three
times.
Chromatin immunoprecipitation (ChIP)
ChIP assay was performed with a commercial Kit (Milli-
pore 17-371). Briefly, formaldehyde was added to the
medium to a final concentration of 1% and incubated for
10 min at room temperature, followed by addition of gly-
cine (0.125 M) and incubation for another 5 min. The
f i x e dc e l l sw e r es c r a p e di n t oc onical tubes, pelleted, and
lysed in a SDS lysis buffer containing protease inhibitor
(Roche). DNA was sheared to fragments of 500-1000 bp
by sonication. The chromatin was precleared with sal-
mon sperm DNA/protein G-agarose slurry for 90 min at
4°C. The precleared supernatant was incubated with anti-
bodies against acetylation histone H3 (K9), histone H3 or
normal rabbit IgG overnight at 4°C. The immunocom-
plexes were eluted with elution buffer (1% SDS and 0.1
MN a H C O 3) after washing. NaCl was added into eluted
samples (final concentration 0.2 M) to reverse histone-
DNA cross-links and the samples were heated for 4 hrs
at 65°C. The purified DNA was used for PCR reactions.
Primers for PCR amplification of the ATX promoter
DNA were 5’-ATGATAGCTTAAGCCTCTTAGG-3’
and 5’-TGCAGCGTGTTCTCTTTGCCTT-3’.P C Rw a s
carried out for 35 cycles (95°C for 40 s, 60°C for 40 s, and
72°C for 40 s), and PCR products were resolved on 2%
agarose gel.
Measurement of apoptosis
Cells were subjected to TSA treatment in the serum-free
conditional medium containing 250 μg/ml fatty-acid free
BSA. To test the effects of LPC and LPA on TSA-
induced apoptosis, cells were starved for 16 hrs in
serum-free conditional medium before the TSA treat-
ment in the presence of LPA or LPC. Apoptosis assays
of the TSA-treated cells were performed by PI staining
and FACS analysis as described previously [30,49].
Statistical analysis
Data was analyzed by Student’s t-test for two-group
comparison. The values sho w ni nt h eg r a p ha r et h e
mean ± S.D, and the p value derived from Student’st
test is (*) p < 0.005, (**) p < 0.001.
Additional material
Additional file 1: figure S1 - HDAC inhibitors, NaB and VPA,
upregulate ATX expression in different cancer cells. Hela, MDA-MB-
231 and Du145 cells were treated with NaB (1 mM) or VPA (1 mM) for
24 hrs, and then the ATX mRNA expression levels were evaluated by
RT-PCR.
Additional file 2: figure S2 - Knockdown of individual HDAC alone
could not up-regulate ATX expression. SW480 cells were transfected
with the indicated HDAC siRNA with non-specific siRNA (siNC) as control.
Total RNA was extracted at 48 hrs post transfection, and then the mRNA
expression levels of HDACs and ATX in SW480 cells were detected by
RT-PCR.
Additional file 3: figure S3 - BrP-LPA and S32826 inhibited ATX
lysoPLD activity. SW480 cells were treated with or without TSA (100
nM) for 24 hrs. After treatment, the conditional culture medium was
collected and concentrated about 30-fold. Different doses of BrP-LPA (A)
or S32826 (B) were added to the concentrated conditional medium as
indicated. After incubation for 1 hr, LysoPLD activity in the conditional
medium was determined with FS-3 as substrate as described in Methods.
Additional file 4: figure S4 - ATX inhibitor S32826 enhanced the
TSA-induced cell apoptosis. The SW480 (A), MDA-MB-231 (B), colo320
(C) and MDA-MB-435 (D) cells were pretreated with or without ATX
inhibitor S32826 (1 μM) for 1 hr, and then treated with TSA (250 nM) in
the presence of LPC (100 μM) or LPA (5 μM) as indicated. The cell
apoptosis was measured after TSA treatment for 24 hrs. The p values
derived from Student’s t test are (*) p < 0.005, (**) p < 0.001.
Additional file 5: figure S5 - Histone acetylation in ATX promoter
region is insufficient to up-regulate ATX expression. A, SW480 and
HT-29 cells were treated with or without TSA (100 nM) for 24 hrs, and
then subjected to ChIP assays as described in Methods to detect the
acetylated histone H3 in the ATX promoter region. ATX expression levels
were detected by RT-PCR. B, SW480 cells were transfected with HDAC3
and/or HDAC7 siRNA(s) as indicated. The ChIP assays were performed 48
hrs post transfection to detect the acetylated histone H3 in ATX
promoter region. The acetylation level of histone H3 (Lys9) in SW480 cell
lysates was detected by Western blot analyses and normalized by the
total histone H3.
Additional file 6: figure S6 - Inhibition of ATX-LPA signaling
enhanced TSA-induced apoptosis in serum-containing medium. The
MDA-MB-231 cells were treated with TSA (1 μM) for 48 hrs in the
conditional serum-free medium or serum (10%)-containing medium to
detect the effect of serum on TSA-induced apoptosis. Furthermore, in
serum (10%)-containing medium, MDA-MB-231 cells were pretreated
with ATX inhibitor S32826 (1 μM) or LPA1/3 inhibitor Ki16425 (1 μM) for 1
hr, and then treated with TSA (1 μM) for 48 hrs. The cell apoptosis was
measured after TSA treatment. The p value derived from Student’s t test
is (**) p < 0.001.
Abbreviations
ATX: Autotaxin; TSA: trichostatin A; HDAC: Histone deacetylase; HDACi: HDAC
inhibitor; LysoPLD: lysophospholipase D; BrP: LPA-butylphosphonate
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